DELTA-TYPE OPIOID RECEPTOR

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 12:08:19 GMT 2023` Edited by `admin` on `Sat Dec 16 12:08:19 GMT 2023`
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	EV0PWK6TT6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DELTA-TYPE OPIOID RECEPTOR

Common Name

English

delta (DOP)

Common Name

English

DOR-1

Common Name

English

OPRD

Common Name

English

Code System Code Type Description

PHAROS

P41143

Created by admin on Sat Dec 16 12:08:22 GMT 2023 , Edited by admin on Sat Dec 16 12:08:22 GMT 2023

PRIMARY

FDA UNII

EV0PWK6TT6

Created by admin on Sat Dec 16 12:08:22 GMT 2023 , Edited by admin on Sat Dec 16 12:08:22 GMT 2023

PRIMARY

UNIPROT

P41143

Created by admin on Sat Dec 16 12:08:22 GMT 2023 , Edited by admin on Sat Dec 16 12:08:22 GMT 2023

PRIMARY

From	To
1_121	1_198

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_18
N	1_33

Related Record Type Details


					EPL8W5565D

PROGLUMIDE

AGONIST -> TARGET

Amount:


					36B82AMQ7N

NALOXONE

INHIBITOR -> TARGET

Qualification:

IC50

Amount:


					A59U94JDE5

MP-135

PARTIAL AGONIST->TARGET

Comments:

EMAX = 28% OF DAMGO

Qualification:

EC50

Amount:


					7ATC8US66S

BW-942C

AGONIST -> TARGET


					958Y70F3HQ

AZD-7268

AGONIST -> TARGET

Interaction Type:

SELECTIVE


					G167Z38QA4

NALTRINDOLE

INHIBITOR -> TARGET

Amount:


					UY7TB22PB7

TAN-67

AGONIST -> TARGET

Amount:


					7GDW9S3GN3

CEBRANOPADOL

AGONIST -> TARGET

Amount:


					45TPJ4MBQ1

ELUXADOLINE

INHIBITOR -> TARGET

Amount:


					NT43S9BKJ2

AT-076

INHIBITOR -> TARGET

Interaction Type:

ANTAGONIST


					YQ6D119I11

N-(C11)METHYLNALTRINDOLE

RADIOLIGAND->TARGET


					CVL1MSR5Z2

CMX-020

PARENT->INNOVATOR


					9JEZ9OD3AS

METENKEFALIN

AGONIST -> TARGET

Amount:


					QV897JC36D

BUTORPHANOL

AGONIST -> TARGET


					MQS88P23Q4

NALDEMEDINE-CARBOXYLIC ACID

INHIBITOR -> TARGET


					40D3SCR4GZ

BUPRENORPHINE

AGONIST -> TARGET


					LK61N6FL38

LY-2795050 C-11

RADIOLIGAND->OFF TARGET

Qualification:

Amount:


					L842QB22SW

SNC-80

AGONIST -> TARGET

Comments:

SELECTIVE FOR DELTA AND DELTA-MU heteromers[

Amount:


					DUK8PZ84YX

NOR-NALDEMEDINE

INHIBITOR -> TARGET


					CSJ43DHV6P

NALDEMEDINE 3-O-.BETA.-D-GLUCURONIDE

INHIBITOR -> TARGET


					39K8JHE8XN

U-50488

LIGAND->TARGET

Comments:

WEAK BINDER

Interaction Type:

BINDING

Qualification:

IC50

Amount:


					7W2581Z5L8

SAMIDORPHAN

PARTIAL AGONIST->TARGET


					4CGN6NS048

AMDAKEFALIN

AGONIST -> TARGET


					CD35PMG570

OXYCODONE

AGONIST -> TARGET


					CQK2YXW6EZ

DADLE

AGONIST -> TARGET

Qualification:

Amount:


					LK97CY7UA6

NALDEMEDINE 6-O-.BETA.-D-GLUCURONIDE

INHIBITOR -> TARGET


					UF599785JZ

FENTANYL

NON-INHIBITOR->OFF TARGET

Amount:


					L2T84IQI2K

NALBUPHINE

INHIBITOR -> TARGET

Amount:


					03KSI6WLXH

NALDEMEDINE

INHIBITOR -> TARGET


					HNS3BS73HT

DADLE H-3

RADIOLIGAND->TARGET

Qualification:

Amount:


					H58945J6KL

Diprenorphine H-3

RADIOLIGAND->TARGET

Qualification:

Amount:


					2SEC01B703

DERMORPHIN

WEAK AGONIST->TARGET

Amount:


					BKA67VHE3B

MITRAGYNINE PSEUDOINDOXYL

INHIBITOR -> TARGET

Amount:


					HB4QD9GL6F

DPDPE

AGONIST -> TARGET

Qualification:

Amount:


					D343S4VX5G

THIOBROMADOL

AGONIST -> TARGET

Comments:

In the MVD, C8813 could inhibit the electrically induced contraction, but weaker than in the GPI. Moreover, this inhibitory effect could antagonized by the δ-opioid receptor antagonist ICI174864. These results indicated C8813 also acted on δ-opioid receptor but less potent than on μ-opioid receptor.

Amount: